Brenig Therapeutics Initiates Phase 1 Trial of BT-267 for Parkinson's Disease
核心洞察
Brenig Therapeutics (搜索) has commenced a first-in-human trial of BT-267, a novel LRRK2 (搜索) inhibitor, for both idiopathic and LRRK2-associated Parkinson's disease (搜索).
The Phase 1 trial will initially assess the safety and tolerability of BT-267 in healthy volunteers, followed by proof-of-concept studies in Parkinson's patients.
Preclinical data suggest BT-267 has a superior safety profile and exceptional pharmacokinetics, including high cerebrospinal fluid penetration.
Brenig Therapeutics (搜索) has announced the start of a Phase 1 clinical trial for BT-267, a selective LRRK2 (搜索) inhibitor, as a potential treatment for Parkinson's disease (搜索). The trial, which began in November 2024, will evaluate the safety and tolerability of BT-267 in healthy volunteers before moving to proof-of-concept studies in patients with idiopathic Parkinson's disease.
BT-267 is designed to address both idiopathic and LRRK2 (搜索)-associated Parkinson's disease (搜索). The development of BT-267 was supported by a $65 million financing round led by New Enterprise Associates.
Preclinical Profile of BT-267
Preclinical data indicates that BT-267 has a favorable safety profile compared to other LRRK2 (搜索) inhibitors. GLP toxicology studies showed minimal lung or kidney morphological changes at the highest doses tested. The compound also exhibits exceptional pharmacokinetics, including a high cerebrospinal fluid (CSF) to plasma unbound ratio, suggesting effective brain penetration.
Innovative Development Approach
BT-267's development incorporates computer-aided drug design, AI/ML computational pharmacology, biomarker models, and structural biology expertise. This approach aims to identify predictive biomarkers that could help position BT-267 as a disease-modifying therapy for Parkinson's disease (搜索), including idiopathic cases without known genetic drivers.
Parkinson's Disease Context
Parkinson's disease (搜索) is a progressive neurodegenerative disorder affecting millions worldwide. Current treatments primarily manage symptoms, with a significant unmet need for therapies that can modify the disease's progression. LRRK2 (搜索) is a promising therapeutic target, and BT-267 represents a potential advancement in this area.